ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Astellas boosts Cytokinetics pact

by Michael McCoy
August 1, 2016 | APPEARED IN VOLUME 94, ISSUE 31

The Japanese drugmaker Astellas Pharma has expanded its collaboration with Cytokinetics, a biotech firm focused on muscle activators. Astellas will pay $65 million for an option to commercialize tirasemtiv, a skeletal muscle activator now in a Phase III clinical trial as an amyotrophic lateral sclerosis (ALS) treatment. The Japanese firm will also put up $30 million to fund development of Cytokinetics’ CK-2127107 for ALS. Astellas had already licensed the compound for other muscle diseases.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment